PortfoliosLab logoPortfoliosLab logo
CTMX vs. CNTB
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

CTMX vs. CNTB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CytomX Therapeutics, Inc. (CTMX) and Connect Biopharma Holdings Limited (CNTB). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CTMX vs. CNTB - Yearly Performance Comparison


2026 (YTD)2025
CTMX
CytomX Therapeutics, Inc.
10.33%100.94%
CNTB
Connect Biopharma Holdings Limited
-7.09%41.71%

Fundamentals

Market Cap

CTMX:

$799.88M

CNTB:

$145.40M

EPS

CTMX:

-$0.11

CNTB:

-$1.03

PS Ratio

CTMX:

9.55

CNTB:

5.58

PB Ratio

CTMX:

8.08

CNTB:

2.04

Total Revenue (TTM)

CTMX:

$76.20M

CNTB:

$26.08M

Gross Profit (TTM)

CTMX:

$75.69M

CNTB:

$24.93M

EBITDA (TTM)

CTMX:

-$19.39M

CNTB:

-$56.30M

Returns By Period

In the year-to-date period, CTMX achieves a 10.33% return, which is significantly higher than CNTB's -7.09% return.


CTMX

1D
6.58%
1M
-12.48%
YTD
10.33%
6M
47.34%
1Y
639.23%
3Y*
46.01%
5Y*
-9.80%
10Y*
-9.91%

CNTB

1D
-9.66%
1M
6.07%
YTD
-7.09%
6M
73.51%
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CTMX vs. CNTB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CTMX
CTMX Risk / Return Rank: 9898
Overall Rank
CTMX Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
CTMX Sortino Ratio Rank: 9898
Sortino Ratio Rank
CTMX Omega Ratio Rank: 9797
Omega Ratio Rank
CTMX Calmar Ratio Rank: 9999
Calmar Ratio Rank
CTMX Martin Ratio Rank: 9999
Martin Ratio Rank

CNTB
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CTMX vs. CNTB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CytomX Therapeutics, Inc. (CTMX) and Connect Biopharma Holdings Limited (CNTB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CTMXCNTBDifference

Sharpe ratio

Return per unit of total volatility

3.81

Sortino ratio

Return per unit of downside risk

4.71

Omega ratio

Gain probability vs. loss probability

1.61

Calmar ratio

Return relative to maximum drawdown

15.76

Martin ratio

Return relative to average drawdown

36.65

CTMX vs. CNTB - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


CTMXCNTBDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.81

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.07

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.09

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.08

0.62

-0.70

Correlation

The correlation between CTMX and CNTB is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

CTMX vs. CNTB - Dividend Comparison

Neither CTMX nor CNTB has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CTMX vs. CNTB - Drawdown Comparison

The maximum CTMX drawdown since its inception was -98.74%, which is greater than CNTB's maximum drawdown of -33.81%. Use the drawdown chart below to compare losses from any high point for CTMX and CNTB.


Loading graphics...

Drawdown Indicators


CTMXCNTBDifference

Max Drawdown

Largest peak-to-trough decline

-98.74%

-33.81%

-64.93%

Max Drawdown (1Y)

Largest decline over 1 year

-41.14%

Max Drawdown (5Y)

Largest decline over 5 years

-95.65%

Max Drawdown (10Y)

Largest decline over 10 years

-98.74%

Current Drawdown

Current decline from peak

-86.27%

-29.00%

-57.27%

Average Drawdown

Average peak-to-trough decline

-70.40%

-17.10%

-53.30%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.69%

Volatility

CTMX vs. CNTB - Volatility Comparison


Loading graphics...

Volatility by Period


CTMXCNTBDifference

Volatility (1M)

Calculated over the trailing 1-month period

53.47%

Volatility (6M)

Calculated over the trailing 6-month period

74.27%

Volatility (1Y)

Calculated over the trailing 1-year period

169.33%

100.81%

+68.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

142.15%

100.81%

+41.34%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

111.35%

100.81%

+10.54%

Financials

CTMX vs. CNTB - Financials Comparison

This section allows you to compare key financial metrics between CytomX Therapeutics, Inc. and Connect Biopharma Holdings Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00M50.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
663.00K
48.00K
(CTMX) Total Revenue
(CNTB) Total Revenue
Values in USD except per share items